Journal article
Considerations for the safe prescribing and use of COX-2-specific inhibitors
DR Barraclough, JV Bertouch, P Brooks, MA Brown, LG Cleland, LE Clemens, SJ Crowley, RO Day, JP DeJager, JP Edmonds, PJ Fletcher, GR Franks, DC Harris, JD Horowitz, MD Johnston, SJ Kerr, GO Littlejohn, GJ MacDonald, GJ McColl, PN Sambrook Show all
Medical Journal of Australia | AUSTRALASIAN MED PUBL CO LTD | Published : 2002
Abstract
The majority of the "Australian COX-2-Specific Inhibitor (CSI) Prescribing Group" endorse the following points: ■ CSIs are equivalent to non-steroidal anti-inflammatory drugs (NSAIDs) as anti-inflammatory agents. ■ CSIs and NSAIDs modify symptoms but do not alter the course of musculoskeletal disease. ■ CSIs do not eliminate the occurrence of ulcers or their serious complications, but are associated with considerably fewer peptic ulcers, slightly fewer upper GI symptoms and, according to published reports, fewer serious upper GI complications, notably bleeding, than NSAIDs. ■ CSIs and NSAIDs have similar effects on renal function and blood pressure. ■ Whether any CSI poses a risk to cardiova..
View full abstract